EuroPharma and New Chapter agree dist deal
Natural health products developer EuroPharma and fellow US firm New Chapter, a producer of probiotic nutrients and herbal supplements, have signed an agreement under which the latter will act as exclusive distributor for the former's product Vectomega.
Vectomega combines a naturally-occurring complex of five phospholipids with the omega-3 oils docosahexaenoic acid and eicosapentaenoic acid, as well as beneficial proteins and amino acids, in a highly bioavailable form.
Europharma said that it is the only product of its type to provide omega-3 oils in their natural phospholipid setting without the use of heat, solvents or chemical modification. It added that studies have revealed that, when the product is taken, around 50 times the amount of both DHA and EPA crosses cellular membranes, compared with other commercially available forms of the two oils.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze